Who
Adeoye Y. Olukotun
Director
Company insider
Files Form 4 as: Director, Arrowhead Pharmaceuticals; Director, Tonix Pharmaceuticals Holding; Director, diaDexus; Director, Bioclinica; Director, Icagen; Chief Medical Officer, VIA Pharmaceuticals.
In numbers
- Trades disclosed
- 62
- Buys
- 1
- Sells
- 7
- Bought
- $5,029
- Sold
- $2.1M
- Companies
- 6
- Companies where not an officer
- 5
- First trade
- 3 Aug 2006
- Last trade
- 18 Aug 2026
- Last filed
- 20 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Aug 2026filed 20 Aug 2026 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $174K2,000 at $86.96 | filing |
| 18 Aug 2026filed 20 Aug 2026 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $174K2,000 at $86.96 | filing |
| 12 May 2026filed 14 May 2026 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,700 at $0.00 | filing |
| 12 May 2026filed 14 May 2026 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,700 at $0.00 | filing |
| 19 Dec 2025filed 23 Dec 2025 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $206K3,090 at $66.70 | filing |
| 19 Dec 2025filed 23 Dec 2025 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $414K6,083 at $68.04 | filing |
| 19 Dec 2025filed 23 Dec 2025 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $57K827 at $68.48 | filing |
| 16 Dec 2025filed 18 Dec 2025 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —7,819 at $0.00 | filing |
| 13 May 2025filed 15 May 2025 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 23 Jan 2025filed 27 Jan 2025 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $20K959 at $21.00 | filing |
| 27 Dec 2024filed 30 Dec 2024 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $57K2,850 at $20.00 | filing |
| 18 Dec 2024filed 20 Dec 2024 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Code A | $385K16,733 at $22.99 | filing |
| 10 Jun 2024filed 28 Feb 2025 | TNXP Tonix Pharmaceuticals HoldingBiotechnology | SEC FORM 4 Code J | $20.81 at $1.91 | filing |
| 23 May 2024filed 24 May 2024 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —104,621 at $0.00 | filing |
| 15 Dec 2023filed 19 Dec 2023 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Code A | $381K14,987 at $25.41 | filing |
| 8 May 2023filed 10 May 2023 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 3 Mar 2023filed 6 Mar 2023 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $371K11,350 at $32.65 | filing |
| 10 Jan 2023filed 11 Jan 2023 | ARWR Arrowhead Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,593 at $0.00 | filing |
| 10 Jan 2023filed 11 Jan 2023 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —7,867 at $0.00 | filing |
| 9 May 2022filed 11 May 2022 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,131,500 at $0.00 | filing |
News
Head-To-Head Review: DBV Technologies (NASDAQ:DBVT) vs. Arrowhead Pharmaceuticals (NASDAQ:ARWR)ARWR · dailypolitical.com · 21 Oct 2026Arrowhead Pharmaceuticals (NASDAQ:ARWR) versus Sera Prognostics (NASDAQ:SERA) Head to Head ReviewARWR · themarketsdaily.com · 18 Oct 2026
0 headlines in the last 90 days name Adeoye Y. Olukotun; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.